Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 with serplulimab and chemotherapy in advanced sqNSCLC
NCT07318883Phase 3Not yet recruiting
- Sponsor
- Henlius
- Start
- Mar 2026
- Primary completion
- Jan 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pimurutamab in squamous cell carcinoma of the lung (SCCL), sponsored by Henlius. Primary endpoints: Objective Response Rate at 6 months, Progression-Free Survival at 16 months and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
pimurutamab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07318883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318883.